Eindhoven Startup Secures €2 Million for Aorta-Aneurysm Treatment
TripleMed BV, an Eindhoven-based medical startup, has raised over €2 million to fund clinical studies for a novel aorta-aneurysm treatment, aiming for CE-mark certification and market introduction by early 2025.
Innovative Healthtech Solution
TripleMed BV, founded in 2011 by vascular surgeons Dr. Hans Brom, Dr. Alexander de Vries, and Prof. Dr. Michael Jacobs, focuses on innovative solutions for treating aorta-aneurysms. This healthtech venture is dedicated to improving patient outcomes and reducing healthcare costs associated with aorta-aneurysm treatments. Aortic aneurysms, which involve the abnormal bulging of the aorta due to weakened vessel walls, can lead to severe complications if not properly managed.
AneuFix and AneuFill: A Novel Approach
TripleMed’s flagship products, AneuFix Endoleak Repair and AneuFill Prophylactic Sac Filling, are designed to address the limitations of current treatments. AneuFix focuses on repairing leaks that occur in about 10-15% of patients treated with stent-grafts, while AneuFill aims to prevent aneurysm growth by filling the aneurysmal sac. These innovations promise a significant reduction in repeated surgical interventions and associated costs, as well as an improvement in the quality of life for patients.
Clinical Trials and CE-Mark Certification
The recent funding will support ongoing clinical studies in hospitals across the Netherlands and Belgium. TripleMed targets to complete these studies on 57 patients by the end of 2024, with an 89% success rate already demonstrated in stopping leaks. The ultimate goal is to achieve CE-mark certification for AneuFix by early 2025 and subsequently for AneuFill in 2026. This certification will allow TripleMed to market these treatments within the European Economic Area, ensuring compliance with safety and performance standards.
Impact on Global Health
Globally, more than 150,000 patients are treated annually for aorta-aneurysms, with a significant number experiencing complications due to leaks in their stent-grafts. The introduction of TripleMed’s solutions could drastically reduce these numbers and provide a more reliable treatment option. According to Lenn Houbiers, investment manager at LIOF, TripleMed’s approach not only improves the efficiency of treatments but also enhances the quality of life for patients while reducing overall healthcare costs.
Future Prospects
TripleMed’s CEO, Tjeerd Homsma, expressed satisfaction with the new funding, highlighting its importance in achieving the company’s certification and market introduction goals. As the company moves forward, it aims to solidify its position as a leader in the healthtech sector, offering innovative and cost-effective solutions for aorta-aneurysm treatment. The support from investors, including Brightlands Venture Partners managing Chemelot Ventures, underscores the confidence in TripleMed’s potential to revolutionize aorta-aneurysm care.